Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

Walter M. Stadler, Dezheng Huo, Christopher George, Ximing Yang, Christopher Ryan, Theodore Karrison, Todd M. Zimmerman, Nicholas J. Vogelzang

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

Purpose: Combination gemcitabine and 5-fluorouracil (5-FU) may have activity in metastatic renal cell cancer. To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined. Materials and Methods: The survival status of 153 patients with metastatic renal cell cancer treated on 1 phase I and 4 phase II trials of gemcitabine/5-FU based regimens was updated. Univariate and multivariate Cox proportional hazards models were constructed using multiple imputation for missing values. Results: Performance status, prior nephrectomy, number of metastatic sites, decreased albumin and elevated alkaline phosphatase were highly prognostic for survival. Sarcomatoid differentiation and hypercalcemia had borderline prognostic significance. Using a previous described prognostic model that divided patients into 3 risk groups survival in those treated with gemcitabine/5-FU in this series was consistently better than survival in similar patients treated in the Motzer series. Conclusions: Previously described prognostic factors for survival in metastatic renal cancer were confirmed. There is no clearly identifiable group that is most likely to benefit from a gemcitabine/5-FU regimen but there is a continued suggestion that this regimen provides a modest improvement over historical chemotherapy approaches.

Original languageEnglish (US)
Pages (from-to)1141-1145
Number of pages5
JournalJournal of Urology
Volume170
Issue number4 I
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • Antineoplastic combined chemotherapy protocols
  • Carcinoma, renal cell
  • Fluorouracil
  • Kidney

ASJC Scopus subject areas

  • Urology

Cite this

Stadler, W. M., Huo, D., George, C., Yang, X., Ryan, C., Karrison, T., Zimmerman, T. M., & Vogelzang, N. J. (2003). Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. Journal of Urology, 170(4 I), 1141-1145. https://doi.org/10.1097/01.ju.0000086829.74971.4a